Deallus welcomes Kunal Kaushal as a Principal in the New York office

Deallus is delighted to announce that Kunal Kaushal joined our team on the 28th March. Kunal focuses on advising executives in the Medical suite and the Market Access suite of leading global pharmas.

Kunal brings more than 14 years of strategy consulting and advisory experience to the role, his expertise spanning many different project types, geographies, and therapeutic areas. His TA focus includes Oncology, Cardiovascular, Gastrointestinal, Anti-Obesity and Rheumatology.

He is recognized by clients and peers as a consulting leader, particularly in Strategy, Analytics, Data, Medical Affairs effectiveness, as well as Market Access.

In his new role at Deallus, he will lead a small number of key accounts, strengthen select therapeutic area communities, and have a key role in further broadening and formalizing capabilities building.

Kunal’s experience spans various geographies – he has lived and worked in India and New York.

“It was the deep focus on therapeutic expertise and industry knowledge that piqued my interest towards joining Deallus. I am excited to be part of this growing team and bring new capabilities and offerings to our clients. Really look forward towards working with the team and our clients to provide leading strategic intelligence and commercialization advisory.”

Kunal obtained his MBA with honors from ISB Hyderabad with a focus on strategy and his undergraduate in Industrial engineering from IIT Delhi University. He lives in New Jersey with his family, his wife and twins – a boy and a girl that he loves spending his free time with.

Peter Barschdorff, VP and Head of Deallus’ U.S. business adds:

“We’re very fortunate to see Kunal join the Deallus team. Kunal brings unique leadership on the frontier of Value, Access, and Medical, building on past leadership roles and leveraging his impressive set of client experience. We’re thrilled to see, through the addition of Kunal to our leadership team, a strengthening of Deallus’ account leadership capacity as well as the company’s functional capabilities particularly in Medical and in Market Access. I’m excited to introduce Kunal to our clients!”

You may also be interested in…

  • Post-ASCO 2022- Summary of key breast cancer highlights

Post-ASCO 2022: Summary of key breast cancer highlights

With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.